Transgene and NEC Bio Announce License Agreement
On April 2, 2026, Transgene S.A., a biotechnology company focused on viral vector-based immunotherapies for cancer, and NEC Bio B.V., a subsidiary of NEC Corporation, signed a license agreement to advance the clinical development of TG4050, a personalized neoantigen therapeutic vaccine for HPV-negative head and neck cancers after surgery, according to GlobeNewswire PE. The agreement grants Transgene access to NEC’s AI-based platform for predicting neoantigens to support TG4050’s development in adjuvant treatment.
Details of TG4050 and the Technology
TG4050 is an individualized immunotherapy based on the Modified Vaccinia Ankara vector that incorporates neoantigens selected using NEC’s AI-driven platform, which employs machine learning to identify immunogenic mutations. According to the agreement, TG4050 targets genetic mutations specific to a patient’s tumor to stimulate the immune system and is currently being evaluated in patients with head and neck cancer to prevent relapse and extend disease-free survival after surgery and adjuvant treatment. NEC retains full ownership and operational control of its AI platform while supporting Transgene in subsequent clinical activities.
Financial Terms of the Agreement
Under the license agreement, NEC will receive 2.5 million euros in Transgene shares upon signing and an additional 2.5 million euros in cash paid in tranches until the beginning of 2028, as outlined in the announcement from GlobeNewswire PE. Further payments include milestone-based compensation, partly in Transgene shares, and potential additional amounts tied to development progress, though specific figures for these are confidential. NEC may also receive a percentage of future revenues, details of which are not disclosed.
Rights and Future Development
The agreement provides Transgene with the necessary rights for the continued clinical development, commercialization, and potential partnerships for TG4050 in treating HPV-negative head and neck cancers after surgery, according to GlobeNewswire PE. As a widely-known context, biotechnology licensing deals often involve technology access and financial exchanges, similar to this arrangement where NEC’s AI expertise supports oncology advancements.
